# Sample size and Power calculations Exercises 

Valeria Vitelli<br>Oslo Centre for Biostatistics and Epidemiology<br>Department of Biostatistics, UiO<br>valeria.vitelli@medisin.uio.no

MF9130E - Introductory Course in Statistics 08.05.2023

## Exercise 1

A study is being planned to examine the effectiveness of aciclovir suspension ( $15 \mathrm{mg} / \mathrm{kg}$ ) for treating 1-7 year old children with herpetic gingivostamatitis lasting less than 72 h . It will be a randomized double-blind placebo-controlled trial with "treatment" administered five times a day for 7 days. The main outcome measure for determining sample size is duration of oral lesions.

## Exercise 1

a) How many children are required to have a $90 \%$ power of detecting a 2.5 day difference in duration of oral lesions between the two groups at the $5 \%$ level of significance? The investigators assume that the standard deviation of oral lesions is approximately 5 days.
b) If the difference we want to detect increases to 3 days, what is then the required sample size?
c) If the standard deviation increases to 6 days, what is then the required sample size? (keep a 3 day difference)

## Exercise 2

We aim at comparing the incidence of pelvic pain in two groups of women: a treatment group that has undergone a program of preventive exercises with a physiotherapist, and a control group. The probabilities of pelvic pain in these two groups are $p_{2}$ and $p_{1}$, respectively. The incidence of pelvic pain in the control group is $15 \%$. It is considered important to discover if the incidence is reduced to $8 \%$ in the preventive treatment group. Power is set to $80 \%$ and the significance level to $5 \%$. How many women do we need in each trial group?

## Exercise 3

One group is treated with cholesterol-lowering drug and one group receives placebo. Cholesterol has a standard deviation of $1 \mathrm{mmol} / \mathrm{I}$. The clinically relevant difference between the groups that we want to detect is $0.5 \mathrm{mmol} / \mathrm{l}$. Power is set to $80 \%$ and the significance level to $5 \%$. How many individuals do we need in each group?

## Exercise 4

We want to estimate the incidence of a particular characteristic among women in a given age group and plan to examine a representative sample of women.
a) The uncertainty in the estimate should not exceed $\pm 10 \%$. Expected occurrence is estimated to be $50 \%$. How many women must be in the sample?
b) The uncertainty in the estimate should now not exceed $\pm 3 \%$. Expected occurrence is still $50 \%$. How many women must there be in the sample?
c) The uncertainty in the estimate remains $\pm 3 \%$, but the expected occurrence is now $20 \%$. How many women must there be in the sample?

## Exercise 5

A randomized placebo-controlled trial was carried out to investigate the capacity of aspirin to prevent pregnancy-induced hypertension and preeclamptic toxaemia. The study was carried out on women at high risk of these conditions.
a) How many patients would have been needed to have a $80 \%$ power of detecting as significant $(p<0.05)$ a reduction of one-third in the risk of hypertension from $30 \%$ to $20 \%$ ?

## Exercise 5

b) The actual sample size was 65 . What was the power of the study to detect the difference considered in a)?
c) The observed rates of hypertension were $11 / 31(36 \%)$ in the placebo group and $4 / 34(12 \%)$ in the aspirin group. The authors also quoted a relative risk (RR) of hypertension of 0.33 for aspirin vs placebo. Calculate a $95 \%$ confidence interval of the RR, and comment on the authors' conclusion that large scale clinical trials are needed.

